OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

A phase 1/2 trial of Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasms, run by AbbVie, active and no longer recruiting.